Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Growth charts

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    55 result(s) found for: Growth charts. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2019-004838-41 Sponsor Protocol Number: CSOK583A12301 Start Date*: 2021-03-04
    Sponsor Name:Hexal AG
    Full Title: A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascula...
    Medical condition: The ‘wet’ form of age-related macular degeneration (AMD) is a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by choro...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) LV (Completed) FR (Completed) SK (Completed) BG (Completed) HU (Completed) PT (Completed) AT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-004749-17 Sponsor Protocol Number: FFR101747 Start Date*: 2005-03-22
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, double-blind, placebo-controlled, 2-week crossover, knemometric assessment of the effect of once daily GW685698X Aqueous Nasal Spray 100 mcg on short term growth in children ages 6 - ...
    Medical condition: Seasonal and/or perennial allergic rhinitis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002974-28 Sponsor Protocol Number: NN8640-4468 Start Date*: 2023-07-12
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing the efficacy and safety of once weekly dosing of somapacitan with daily Norditropin® in Chinese children with growth hormone deficiency
    Medical condition: Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-001855-15 Sponsor Protocol Number: QBGJ398-203 Start Date*: 2022-02-02
    Sponsor Name:QED Therapeutics, Inc.
    Full Title: Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL OLE
    Medical condition: Achondroplasia in Children
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10000452 Achondroplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000874-92 Sponsor Protocol Number: LUM-201-01 Start Date*: 2021-03-22
    Sponsor Name:Lumos Pharma, Inc.
    Full Title: A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficie...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002626-23 Sponsor Protocol Number: CRFB002A2411 Start Date*: 2013-11-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen,...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) BE (Completed) DE (Completed) SK (Completed) GB (Completed) HU (Completed) PT (Completed) DK (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002551-22 Sponsor Protocol Number: HZA114971 Start Date*: 2017-02-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg once dai...
    Medical condition: Paediatric Subjects with Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003517-33 Sponsor Protocol Number: CRFB002A2302 Start Date*: 2005-11-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal...
    Medical condition: Male and female patients ≥50 years of age with either with predominantly classic, minimally classic, or occult lesions with no classic component, all with primary or recurrent subfoveal CNV seconda...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) DE (Completed) ES (Completed) PT (Completed) GB (Completed) CZ (Completed) IT (Completed) BE (Completed) FI (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002931-32 Sponsor Protocol Number: APL2-GA-305 Start Date*: 2021-09-17
    Sponsor Name:Apellis Pharmaceuticals Inc.
    Full Title: A Phase 3 open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration
    Medical condition: Geographic Atrophy Secondary to Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10063947 Geographic atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002431-18 Sponsor Protocol Number: NN9536-4451 Start Date*: 2019-09-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents with overweight or obesity
    Medical condition: Overweight Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) IE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001145-11 Sponsor Protocol Number: TransCon_hGH_CT-301 Start Date*: 2018-02-12
    Sponsor Name:Ascendis Pharma Endocrinology Division A/S
    Full Title: A multicenter, Phase 3, randomized, open-label, active-controlled, parallel-group trial investigating the safety, tolerability, and efficacy of TransCon hGH administered once a week versus standard...
    Medical condition: Growth hormone deficiency (GHD) in prepubertal children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BG (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002851-92 Sponsor Protocol Number: AN-EPI3334 Start Date*: 2016-09-08
    Sponsor Name:ANTHERA Pharmaceuticals, Inc.
    Full Title: An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis
    Medical condition: Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) PL (Prematurely Ended) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000546-34 Sponsor Protocol Number: NN8022-4392 Start Date*: 2021-02-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomised, placebo-controlled trial
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) PT (Trial now transitioned) NO (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2012-005417-38 Sponsor Protocol Number: CRFB002G2301 Start Date*: 2013-07-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to ...
    Medical condition: Visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    17.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) LV (Completed) PT (Completed) HU (Completed) CZ (Completed) ES (Completed) LT (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-007455-14 Sponsor Protocol Number: QV-001/2007-Pae Start Date*: 2008-06-13
    Sponsor Name:TEVA UK Ltd
    Full Title: A single-centre, open-label, randomised, 2-way cross-over study to determine the effects on the short-term lower leg growth rate between Qvar® 100 μg bd delivered via a metered dose inhaler (MDI) (...
    Medical condition: Short-term lower leg growth rate in children with documented mild to moderate asthma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005607-13 Sponsor Protocol Number: NN8640-4467 Start Date*: 2022-07-15
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with ...
    Medical condition: Short stature born small for gestational age Turner syndrome Noonan syndrome Idiopathic short stature
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10045181 Turner's syndrome PT
    20.0 10010331 - Congenital, familial and genetic disorders 10029748 Noonan syndrome PT
    23.0 100000004859 10066333 Idiopathic short stature LLT
    21.1 100000004868 10041093 Small for gestational age LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) SI (Trial now transitioned) IE (Completed) DE (Trial now transitioned) FI (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019082-29 Sponsor Protocol Number: BFS-AS-305 Start Date*: 2010-08-30
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A double-blind, double-dummy, randomized, placebo- and active-controlled, three-way crossover study to evaluate the effect of Budesonide/Formoterol Spiromax® 80/4.5 mcg Inhalation Powder and Symbic...
    Medical condition: Short term lower leg growth rate in prepubescent children with persistent asthma.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-004959-39 Sponsor Protocol Number: CRFB002A2405 Start Date*: 2013-05-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional a...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) SK (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended) GR (Completed) SE (Completed) FI (Completed) PT (Completed) HU (Completed) NL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000841-22 Sponsor Protocol Number: HZA107112 Start Date*: 2015-08-04
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A randomised, double-blind, two-way crossover study to investigate the effect of inhaled fluticasone furoate on short-term growth in paediatric subjects with asthma
    Medical condition: Chronic disease of the lungs characterized by airway inflammation, bonchoconstriction and increased airway responsiveness.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003272-12 Sponsor Protocol Number: SIVS1012 Start Date*: 2014-04-08
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy
    Medical condition: Proliferative Diabetic Retinopathy (PDR)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 14:08:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA